Navigation Links
Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Date:11/17/2009

CAMBRIDGE, Mass., Nov. 17 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors. The results were presented in a poster session at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston, MA November 15-19, 2009. XMT-1001 is a conjugate of the broad-spectrum cytotoxic camptothecin (CPT) that employs Mersana's Fleximer® platform.

XMT-1001 has continued to demonstrate promising tumor activity and favorable pharmacokinetic and tolerability profiles in the Phase 1 trial. Forty nine patients with refractory solid tumors have received 149 cycles of XMT-1001 at dose levels ranging from 1.0-85 mg CPT equivalents/m2. Twelve of 46 evaluable patients with advanced, refractory tumors demonstrated evidence of at least six weeks of stable disease. Nine of the 12 patients had prolonged stable disease for at least 12 weeks, including two patients for nine months. In addition, pharmacokinetic data for XMT-1001 have demonstrated dose proportional increases in exposure to the drug and confirms the formation of its release products according to the compound's design. The side-effect profile of XMT-1001 has been predictable and no toxicities associated with non-Fleximer-linked CPT or irinotecan, such as hemorrhagic cystitis or severe diarrhea, have been observed. The maximum tolerated dose (MTD) has not been reached and the Phase 1 study continues to accrue patients.

"We are very pleased to see that the data in this ongoing Phase 1 study for XMT-1001 continues to support our goal of establishing proof of concept fo
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Trovagene, Inc. (NASDAQ:   ... that results from two clinical studies will be presented ... Company,s urine-based diagnostic test for the detection of high ... is scheduled to take place in Seattle ... th . Additionally, a new U.S. patent was issued ...
(Date:8/20/2014)... , August 20, 2014 ... of Glenmark Pharmaceuticals Limited India (GPL), announces the ... a novel clinical development candidate, GBR 1302, a ... developed by the Glenmark Biologics Research Centre located ... GBR 1302 is based on Glenmark,s innovative BEAT ...
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Talyst Exhibits at the NPPA Summer Conference 2
(Date:8/20/2014)... Botanica Day Spa ... the new and popular stem cell line from ... and wrinkles and naturally repairs the skin. The ... new service by offering clients a complimentary dermaplaning ... facial. , Pevonia® continues to be a global ...
(Date:8/20/2014)... has been chosen by Plymouth University to be an ... April 2009 to raise awareness of, and funding for, ... brain tumour patients. , A range of events and ... the charity, and members of staff and students, as ... donate, fundraise and volunteer. The involvement of the wider ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 New Jersey’s ... needs of an estimated tens of thousands of patients ... new Bill A3525—a bill that would expand the list ... their own cannabis—earlier this summer by State Assemblywoman Linda ... medicinal quality marijuana is growing. , To help fill ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... Nanophase Technologies (Nasdaq: NANX ) ... products, announced today that the Company accepted the resignation ... Chief Technology Officer, so that he may pursue new ... several of the Company,s key patents and served as ...
... 3 WXYZ is proud to announce that ... Peter Nielsen , will now be seen exclusively on Channel ... than 15 years Peter Nielsen has hosted the nationally syndicated ... the author of numerous books and videos on health and fitness and ...
... the day has surprising impact on young people GAITHERSBURG, ... the importance of breakfast for students, Sodexo, a leading ... 470 school districts across the country, has created a ... time for National School Breakfast Week, March 2-6."Studies repeatedly ...
... to Improve, Automate Health Care in Master-Planned CommunitiesSCOTTSDALE, Ariz., ... of acres across the West but it,s his company,s ... would radically alter the use of energy grids. ... that message this week to The Wall Street Journal,s ...
... Exhibit www.donaldverger.com PORTLAND, Maine, March 3 A ... jail over a period of three days at ... the charges were dismissed, Verger was compelled to ... http://www.newscom.com/cgi-bin/prnh/20090303/NE78221 )"We are deeply grateful to Mr. ...
... of Pennsylvania School of Medicine and the University ... cells that spur misplaced bone growth. Unexpectedly, the ... vessels deep within skeletal muscle and other connective ... work also shows that cells important in the ...
Cached Medicine News:Health News:Nanophase Announces Changes in Principal Officers and Directors 2Health News:Nanophase Announces Changes in Principal Officers and Directors 3Health News:Peter Nielsen Has a New Home on WXYZ-TV! 2Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Innovative Plans by Major Arizona-Based Developer Sparks Landmark Energy Conservation Legislation in Multiple States to Urge Federal Action at Wall Street Journal Conference This Week with Gore, Google CEO & T. Boone Pickens 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 3Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 4Health News:Misplaced metamorphosis 2
Cloward cervical retractor. Size 18 mm....
Large, removable blades, length 242 mm, (9 1/2"). Function: tissue retracting....
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: